[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349815-105":59,"doc-detail-349815-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","loss-of-kdm6a-mediated-genomic-instability-and-metabolic-reprogramming-regulates-response-to-therapeutic-perturbations-in-bladder-cancer-accepted-19-december-2025","Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer - Accepted 19 December 2025","","Loss-of-function mutations in KDM6A occur in about 26% of advanced bladder cancers and associate with poor survival after cisplatin chemotherapy but improved outcomes under anti-PD-1 therapy. CRISPR-Cas9 models show KDM6A deficiency increases extrachromosomal circular DNA carrying chemoresistance loci, driving cisplatin resistance. KDM6A loss also impairs DNA repair and rewires metabolism, reducing glycolysis and lactate output, which lowers histone lactylation in regulatory T cells, suppressing immunoregulatory genes and limiting PD-1hi T-cell expansion.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/loss-of-kdm6a-mediated-genomic-instability-and-metabolic-reprogramming-regulates-response-to-therapeutic-perturbations-in-bladder-cancer-accepted-19-december-2025/349815/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/loss-of-kdm6a-mediated-genomic-instability-and-metabolic-reprogramming-regulates-response-to-therapeutic-perturbations-in-bladder-cancer-accepted-19-december-2025/349815.png","ImageObject",300,407,{"name":92,"@type":93},"Noah","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How do KDM6A loss-of-function mutations affect outcomes in bladder cancer?","Question",{"text":113,"@type":114},"KDM6A loss predicts poor survival after cisplatin-based chemotherapy, while it correlates with improved outcomes with anti-PD-1 therapy.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What mechanism links KDM6A deficiency to cisplatin resistance?",{"text":118,"@type":114},"KDM6A deficiency increases extrachromosomal circular DNA formation that carries chemoresistance loci, promoting cisplatin resistance.",{"name":120,"@type":111,"acceptedAnswer":121},"How does KDM6A loss change tumor metabolism and immune regulation?",{"text":122,"@type":114},"KDM6A loss reduces glycolysis and lactate output, which diminishes histone lactylation in regulatory T cells, suppressing immunoregulatory genes and limiting PD-1hi regulatory T-cell expansion.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},349815,1790142507,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","Article [https://doi.org/10.1038/s41467-025-68132-2](https://doi.org/10.1038/s41467-025-68132-2)  \nLoss ofKDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer  \nReceived: 18 June 2025  \n\n| Accepted: 19 December 2025 |\n| --- |\n| |\n| Check for updates |\n\nPratishtha Singh 1,9, Ranit D’Rozario1,9, Bidisha Chakraborty1,9,  \nSwadhin Meher1,9, Deblina Raychaudhuri1, Aminah J. Tannir1, Yang Li2, Anurag Majumdar1, Jessalyn Hawkins1, Yun Xiong3, Philip Lorenzi3, Padmanee Sharma 1,4,5,6, Kadir Akdemir7, Patrick Pilie4, Abhinav K. Jain 8, Byron Hing Lung Lee 2 & Sangeeta Goswami 1,4,6   \nMutations in epigenetic regulators are common in bladder cancer, yet their impact on therapeutic responses remains unclear. Here, we identify that lossof-function mutations in KDM6A, a histone demethylase altered in about 26% of advanced bladder cancers, are associated with poor survival after cisplatin chemotherapy, whereas they correlate with improved outcomes with anti-PD-1 therapy. Using CRISPR-Cas9-engineered murine and human bladder cancer models, we show that KDM6A deﬁciency increases formation of extrachromosomal circular DNA carrying chemoresistance loci, promoting cisplatin resistance. In parallel, KDM6A loss impairs DNA repair and rewires tumor metabolism, reducing glycolysis and lactate output. This metabolic shift diminishes histone lactylation in regulatory T cells, suppressing immunoregulatory genes and limiting expansion of PD-1hi regulatory T cells. Collectively, ourﬁndings establish KDM6A mutation as a key regulator of therapeutic responses, providing a foundation for its use in guiding precision therapy in advanced bladder cancer.  \nBladder cancer is the sixth most commonly occurring cancer in the United States, with the ﬁve-year overall survival (OS) for advanced bladder cancer being less than 10%1. Cisplatin-based chemotherapy has been a mainstay of therapy for many decades; however the advent of immune checkpoint therapy(ICT) and targeted therapy has changed the current landscape of treatment for bladder cancer2,3.  \nWhile the availability of different therapeutic agents such as chemotherapy, ICT and targeted therapy, either as single agents or in combination, has signiﬁcantly improved outcomes, there remains a lack of biological insight into selecting and sequencing these therapies based on patient attributes to develop a personalized treatment algorithm.  \n1Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 2Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 3Department of Bioinformatics and Computational Biology, Division, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 4Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 5Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 6James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 7Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 8Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 9These authors contributed equally: Pratishtha Singh, Ranit D’Rozario, Bidisha Chakraborty, Swadhin Meher. e-mail: [sgoswami@mdanderson.org](sgoswami@mdanderson.org)  \nThe genes encoding key epigenetic regulators are frequently mutated in bladder cancer4,5. These epigenetic factors orchestrate gene expression, impacting multiple pathways governing cellular phenotype and function6,7. While the impact of mutations in epigenetic factors on initiation and progression of bladder tumorigenesis has been studied8–10, the mechanistic insight into the roles of these mutations in regulating response to therapeutic agents remains largely unexplored. Lys","cbCaiiqmz85np7k8","https://ap.wps.com/l/cbCaiiqmz85np7k8","pdf",5339001,23,"English","# Abstract\n## Clinical association\n## Mechanistic basis in models\n## Metabolic and immune effects\n## Implications for precision therapy","[{\"question\":\"How do KDM6A loss-of-function mutations affect outcomes in bladder cancer?\",\"answer\":\"KDM6A loss predicts poor survival after cisplatin-based chemotherapy, while it correlates with improved outcomes with anti-PD-1 therapy.\"},{\"question\":\"What mechanism links KDM6A deficiency to cisplatin resistance?\",\"answer\":\"KDM6A deficiency increases extrachromosomal circular DNA formation that carries chemoresistance loci, promoting cisplatin resistance.\"},{\"question\":\"How does KDM6A loss change tumor metabolism and immune regulation?\",\"answer\":\"KDM6A loss reduces glycolysis and lactate output, which diminishes histone lactylation in regulatory T cells, suppressing immunoregulatory genes and limiting PD-1hi regulatory T-cell expansion.\"}]","Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer - Accepted 19 December 2025 | PDF",1790085725,58,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/60c3485f89a0a88b824e148843e17714.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1c1d633d768dd79834343197658c9f36.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bf7eaf440ae47dd87f06671f6a3e89ac.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2da540368eaab765886822b349e9d583.webp",980,1301]